Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab

REFERENCES

• Adams, C. W., D. E. Allison, K. Flagella, L. Presta, J. Clarke, N. Dybdal, K. McKeever, and M. X. Sliwkowski. 2006. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother 55:717–727.
   PubMed Web of Science ®Google Scholar
• Agus, D. B., R. W. Akita, W. D. Fox, G. D. Lewis, B. Higgins, P. I. Pisacane, J. A. Lofgren, C. Tindell, D. P. Evans, K. Maiese, H. I. Scher, and M. X. Sliwkowski. 2002. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127–137.
   PubMed Web of Science ®Google Scholar
• Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. Di Fiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813–1821.
   PubMed Web of Science ®Google Scholar
• Atfi, A., E. Dumont, F. Colland, D. Bonnier, A. L′Helgoualc'h, C. Prunier, N. Ferrand, B. Clement, U. M. Wewer, and N. Theret. 2007. The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor. J. Cell Biol. 178:201–208.
   PubMed Web of Science ®Google Scholar
• Bakin, A. V., C. Rinehart, A. K. Tomlinson, and C. L. Arteaga. 2002. p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 115:3193–3206.
   PubMed Web of Science ®Google Scholar
• Berns, K., H. M. Horlings, B. T. Hennessy, M. Madiredjo, E. M. Hijmans, K. Beelen, S. C. Linn, A. M. Gonzalez-Angulo, K. Stemke-Hale, M. Hauptmann, R. L. Beijersbergen, G. B. Mills, M. J. van de Vijver, and R. Bernards. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402.
   PubMed Web of Science ®Google Scholar
• Bianco, R., I. Shin, C. A. Ritter, F. M. Yakes, A. Basso, N. Rosen, J. Tsurutani, P. A. Dennis, G. B. Mills, and C. L. Arteaga. 2003. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812–2822.
   PubMed Web of Science ®Google Scholar
• Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K. A. Schooley, M. Gerhart, R. Davis, J. N. Fitzner, R. S. Johnson, R. J. Paxton, C. J. March, and D. P. Cerretti. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729–733.
   PubMed Web of Science ®Google Scholar
• Caja, L., C. Ortiz, E. Bertran, M. M. Murillo, M. J. Miro-Obradors, E. Palacios, and I. Fabregat. 2007. Differential intracellular signalling induced by TGF-β in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell Signal 19:683–694.
   PubMedGoogle Scholar
• Chang, H. Y., D. S. Nuyten, J. B. Sneddon, T. Hastie, R. Tibshirani, T. Sorlie, H. Dai, Y. D. He, L. J. van't Veer, H. Bartelink, M. van de Rijn, P. O. Brown, and M. J. van de Vijver. 2005. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 102:3738–3743.
   PubMed Web of Science ®Google Scholar
• Cleveland, W. S. 1981. LOWESS: A program for smoothing scatterplots by robust locally weighted regression. Am. Stat. 35:54.
   Web of Science ®Google Scholar
• Debnath, J., S. K. Muthuswamy, and J. S. Brugge. 2003. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30:256–268.
   PubMed Web of Science ®Google Scholar
• Del Castillo, G., M. M. Murillo, A. Alvarez-Barrientos, E. Bertran, M. Fernandez, A. Sanchez, and I. Fabregat. 2006. Autocrine production of TGF-beta confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: role of EGF receptor ligands. Exp. Cell Res. 312:2860–2871.
   PubMedGoogle Scholar
• Derynck, R., R. J. Akhurst, and A. Balmain. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29:117–129.
   PubMed Web of Science ®Google Scholar
• Diaz-Rodriguez, E., J. C. Montero, A. Esparis-Ogando, L. Yuste, and A. Pandiella. 2002. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol. Biol. Cell 13:2031–2044.
   PubMed Web of Science ®Google Scholar
• Dumont, N., and C. L. Arteaga. 2003. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3:531–536.
   PubMed Web of Science ®Google Scholar
• Dumont, N., A. V. Bakin, and C. L. Arteaga. 2003. Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J. Biol. Chem. 278:3275–3285.
   PubMedGoogle Scholar
• Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863–14868.
   PubMed Web of Science ®Google Scholar
• Engelman, J. A., P. A. Janne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B. E. Johnson, and L. C. Cantley. 2005. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 102:3788–3793.
   PubMed Web of Science ®Google Scholar
• Engelman, J. A., J. Luo, and L. C. Cantley. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7:606–619.
   PubMed Web of Science ®Google Scholar
• Engelman, J. A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, and P. A. Janne. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043.
   PubMed Web of Science ®Google Scholar
• Fan, H., C. W. Turck, and R. Derynck. 2003. Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. J. Biol. Chem. 278:18617–18627.
   PubMed Web of Science ®Google Scholar
• Franklin, M. C., K. D. Carey, F. F. Vajdos, D. J. Leahy, A. M. de Vos, and M. X. Sliwkowski. 2004. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317–328.
   PubMed Web of Science ®Google Scholar
• Gobbi, H., W. D. Dupont, J. F. Simpson, W. D. Plummer, Jr., P. A. Schuyler, S. J. Olson, C. L. Arteaga, and D. L. Page. 1999. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia. J. Natl. Cancer Inst. 91:2096–2101.
   PubMedGoogle Scholar
• Goggins, M., M. Shekher, K. Turnacioglu, C. J. Yeo, R. H. Hruban, and S. E. Kern. 1998. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58:5329–5332.
   PubMed Web of Science ®Google Scholar
• Gymnopoulos, M., M. A. Elsliger, and P. K. Vogt. 2007. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. USA 104:5569–5574.
   PubMed Web of Science ®Google Scholar
• Hahn, S. A., M. Schutte, A. T. Hoque, C. A. Moskaluk, L. T. da Costa, E. Rozenblum, C. L. Weinstein, A. Fischer, C. J. Yeo, R. H. Hruban, and S. E. Kern. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353.
   PubMed Web of Science ®Google Scholar
• Harris, L. N., F. You, S. J. Schnitt, A. Witkiewicz, X. Lu, D. Sgroi, P. D. Ryan, S. E. Come, H. J. Burstein, B. A. Lesnikoski, M. Kamma, P. N. Friedman, R. Gelman, J. D. Iglehart, and E. P. Winer. 2007. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13:1198–1207.
   PubMed Web of Science ®Google Scholar
• Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas III, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100:8933–8938.
   PubMed Web of Science ®Google Scholar
• Horowitz, J. C., D. Y. Lee, M. Waghray, V. G. Keshamouni, P. E. Thomas, H. Zhang, Z. Cui, and V. J. Thannickal. 2004. Activation of the prosurvival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-β1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J. Biol. Chem. 279:1359–1367.
   PubMed Web of Science ®Google Scholar
• Izumi, Y., M. Hirata, H. Hasuwa, R. Iwamoto, T. Umata, K. Miyado, Y. Tamai, T. Kurisaki, A. Sehara-Fujisawa, S. Ohno, and E. Mekada. 1998. A metalloprotease-disintegrin, MDC9/meltrin-γ/ADAM9 and PKCδare involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 17:7260–7272.
   PubMed Web of Science ®Google Scholar
• Kenny, P. A., and M. J. Bissell. 2007. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Investig. 117:337–345.
   PubMed Web of Science ®Google Scholar
• Lamb, J., E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J. P. Brunet, A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. A. Armstrong, S. J. Haggarty, P. A. Clemons, R. Wei, S. A. Carr, E. S. Lander, and T. R. Golub. 2006. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935.
   PubMed Web of Science ®Google Scholar
• Markowitz, S., J. Wang, L. Myeroff, R. Parsons, L. Sun, J. Lutterbaugh, R. S. Fan, E. Zborowska, K. W. Kinzler, B. Vogelstein, et al. 1995. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268:1336–1338.
   PubMed Web of Science ®Google Scholar
• Massague, J. 1998. TGF-β signal transduction. Annu. Rev. Biochem. 67:753–791.
   PubMed Web of Science ®Google Scholar
• Massague, J., and Y. G. Chen. 2000. Controlling TGF-β signaling. Genes Dev. 14:627–644.
   PubMed Web of Science ®Google Scholar
• Massague, J., and R. R. Gomis. 2006. The logic of TGFβ signaling. FEBS Lett. 580:2811–2820.
   PubMed Web of Science ®Google Scholar
• Mellinghoff, I. K., M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H. Huang, D. J. Chute, B. L. Riggs, S. Horvath, L. M. Liau, W. K. Cavenee, P. N. Rao, R. Beroukhim, T. C. Peck, J. C. Lee, W. R. Sellers, D. Stokoe, M. Prados, T. F. Cloughesy, C. L. Sawyers, and P. S. Mischel. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353:2012–2024.
   PubMed Web of Science ®Google Scholar
• Montero, J. C., L. Yuste, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella. 2002. Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem. J. 363:211–221.
   PubMedGoogle Scholar
• Moses, H. L., E. L. Branum, J. A. Proper, and R. A. Robinson. 1981. Transforming growth factor production by chemically transformed cells. Cancer Res. 41:2842–2848.
   PubMed Web of Science ®Google Scholar
• Muraoka-Cook, R. S., I. Shin, J. Y. Yi, E. Easterly, M. H. Barcellos-Hoff, J. M. Yingling, R. Zent, and C. L. Arteaga. 2006. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25:3408–3423.
   PubMed Web of Science ®Google Scholar
• Muraoka, R. S., Y. Koh, L. R. Roebuck, M. E. Sanders, D. Brantley-Sieders, A. E. Gorska, H. L. Moses, and C. L. Arteaga. 2003. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol. Cell. Biol. 23:8691–8703.
   PubMed Web of Science ®Google Scholar
• Nagata, Y., K. H. Lan, X. Zhou, M. Tan, F. J. Esteva, A. A. Sahin, K. S. Klos, P. Li, B. P. Monia, N. T. Nguyen, G. N. Hortobagyi, M. C. Hung, and D. Yu. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127.
   PubMed Web of Science ®Google Scholar
• Peng, S. B., L. Yan, X. Xia, S. A. Watkins, H. B. Brooks, D. Beight, D. K. Herron, M. L. Jones, J. W. Lampe, W. T. McMillen, N. Mort, J. S. Sawyer, and J. M. Yingling. 2005. Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 44:2293–2304.
   PubMed Web of Science ®Google Scholar
• Prigent, S. A., and W. J. Gullick. 1994. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:2831–2841.
   PubMed Web of Science ®Google Scholar
• Reddy, P., J. L. Slack, R. Davis, D. P. Cerretti, C. J. Kozlosky, R. A. Blanton, D. Shows, J. J. Peschon, and R. A. Black. 2000. Functional analysis of the domain structure of tumor necrosis factor-α converting enzyme. J. Biol. Chem. 275:14608–14614.
   PubMed Web of Science ®Google Scholar
• Ritter, C. A., M. Perez-Torres, C. Rinehart, M. Guix, T. Dugger, J. A. Engelman, and C. L. Arteaga. 2007. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13:4909–4919.
   PubMed Web of Science ®Google Scholar
• Roberts, A. B., M. A. Anzano, L. C. Lamb, J. M. Smith, and M. B. Sporn. 1981. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc. Natl. Acad. Sci. USA 78:5339–5343.
   PubMed Web of Science ®Google Scholar
• Rousseau, S., M. Papoutsopoulou, A. Symons, D. Cook, J. M. Lucocq, A. R. Prescott, A. O'Garra, S. C. Ley, and P. Cohen. 2008. TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNFα in LPS-stimulated macrophages. J. Cell Sci. 121:149–154.
   PubMed Web of Science ®Google Scholar
• Sahin, U., G. Weskamp, K. Kelly, H. M. Zhou, S. Higashiyama, J. Peschon, D. Hartmann, P. Saftig, and C. P. Blobel. 2004. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 164:769–779.
   PubMed Web of Science ®Google Scholar
• Sawyer, J. S., D. W. Beight, K. S. Britt, B. D. Anderson, R. M. Campbell, T. Goodson, Jr., D. K. Herron, H. Y. Li, W. T. McMillen, N. Mort, S. Parsons, E. C. Smith, J. R. Wagner, L. Yan, F. Zhang, and J. M. Yingling. 2004. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorg. Med. Chem. Lett. 14:3581–3584.
   PubMed Web of Science ®Google Scholar
• Seton-Rogers, S. E., Y. Lu, L. M. Hines, M. Koundinya, J. LaBaer, S. K. Muthuswamy, and J. S. Brugge. 2004. Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Proc. Natl. Acad. Sci. USA 101:1257–1262.
   PubMed Web of Science ®Google Scholar
• She, Q. B., D. Solit, A. Basso, and M. M. Moasser. 2003. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 9:4340–4346.
   PubMed Web of Science ®Google Scholar
• Siegel, P. M., W. Shu, R. D. Cardiff, W. J. Muller, and J. Massague. 2003. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA 100:8430–8435.
   PubMed Web of Science ®Google Scholar
• Soond, S. M., B. Everson, D. W. Riches, and G. Murphy. 2005. ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking. J. Cell Sci. 118:2371–2380.
   PubMedGoogle Scholar
• Ueda, Y., S. Wang, N. Dumont, J. Y. Yi, Y. Koh, and C. L. Arteaga. 2004. Overexpression of HER2 (ErbB2) in human breast epithelial cells unmasks transforming growth factor β-induced cell motility. J. Biol. Chem. 279:24505–24513.
   PubMed Web of Science ®Google Scholar
• Valdes, F., M. M. Murillo, A. M. Valverde, B. Herrera, A. Sanchez, M. Benito, M. Fernandez, and I. Fabregat. 2004. Transforming growth factor-β activates both pro-apoptotic and survival signals in fetal rat hepatocytes. Exp. Cell Res. 292:209–218.
   PubMedGoogle Scholar
• van de Vijver, M. J., Y. D. He, L. J. van't Veer, H. Dai, A. A. Hart, D. W. Voskuil, G. J. Schreiber, J. L. Peterse, C. Roberts, M. J. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, T. van der Velde, H. Bartelink, S. Rodenhuis, E. T. Rutgers, S. H. Friend, and R. Bernards. 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999–2009.
   PubMed Web of Science ®Google Scholar
• Vijapurkar, U., M. S. Kim, and J. G. Koland. 2003. Roles of mitogen-activated protein kinase and phosphoinositide 3′-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. Exp. Cell Res. 284:291–302.
   PubMedGoogle Scholar
• Vinals, F., and J. Pouyssegur. 2001. Transforming growth factor β1 (TGF-β1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling. Mol. Cell. Biol. 21:7218–7230.
   PubMed Web of Science ®Google Scholar
• Wakefield, L. M., and A. B. Roberts. 2002. TGF-β signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12:22–29.
   PubMed Web of Science ®Google Scholar
• Wang, D., T. Kanuma, H. Mizunuma, F. Takama, Y. Ibuki, N. Wake, A. Mogi, Y. Shitara, and S. Takenoshita. 2000. Analysis of specific gene mutations in the transforming growth factor-β signal transduction pathway in human ovarian cancer. Cancer Res. 60:4507–4512.
   PubMed Web of Science ®Google Scholar
• Wang, J., L. Sun, L. Myeroff, X. Wang, L. E. Gentry, J. Yang, J. Liang, E. Zborowska, S. Markowitz, J. K. Willson, et al. 1995. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem. 270:22044–22049.
   PubMed Web of Science ®Google Scholar
• Wang, M. Y., K. V. Lu, S. Zhu, E. Q. Dia, I. Vivanco, G. M. Shackleford, W. K. Cavenee, I. K. Mellinghoff, T. F. Cloughesy, C. L. Sawyers, and P. S. Mischel. 2006. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66:7864–7869.
   PubMed Web of Science ®Google Scholar
• Wang, S. E., A. Narasanna, M. Perez-Torres, B. Xiang, F. Y. Wu, S. Yang, G. Carpenter, A. F. Gazdar, S. K. Muthuswamy, and C. L. Arteaga. 2006. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25–38.
   PubMed Web of Science ®Google Scholar
• Wang, S. E., I. Shin, F. Y. Wu, D. B. Friedman, and C. L. Arteaga. 2006. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor β. Cancer Res. 66:9591–9600.
   PubMed Web of Science ®Google Scholar
• Wrana, J. L., L. Attisano, R. Wieser, F. Ventura, and J. Massague. 1994. Mechanism of activation of the TGF-β receptor. Nature 370:341–347.
   PubMed Web of Science ®Google Scholar
• Wu, F. Y., S. E. Wang, M. E. Sanders, I. Shin, F. Rojo, J. Baselga, and C. L. Arteaga. 2006. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 66:2162–2172.
   PubMed Web of Science ®Google Scholar
• Yakes, F. M., W. Chinratanalab, C. A. Ritter, W. King, S. Seelig, and C. L. Arteaga. 2002. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62:4132–4141.
   PubMed Web of Science ®Google Scholar
• Yarden, Y., and M. X. Sliwkowski. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127–137.
   PubMed Web of Science ®Google Scholar
• Yi, J. Y., I. Shin, and C. L. Arteaga. 2005. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem. 280:10870–10876.
   PubMed Web of Science ®Google Scholar
• Zhang, Q., S. M. Thomas, V. W. Lui, S. Xi, J. M. Siegfried, H. Fan, T. E. Smithgall, G. B. Mills, and J. R. Grandis. 2006. Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc. Natl. Acad. Sci. USA 103:6901–6906.
   PubMed Web of Science ®Google Scholar
• Zhou, B. B., M. Peyton, B. He, C. Liu, L. Girard, E. Caudler, Y. Lo, F. Baribaud, I. Mikami, N. Reguart, G. Yang, Y. Li, W. Yao, K. Vaddi, A. F. Gazdar, S. M. Friedman, D. M. Jablons, R. C. Newton, J. S. Fridman, J. D. Minna, and P. A. Scherle. 2006. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10:39–50.
   PubMed Web of Science ®Google Scholar